The latest episode of the DDW &#x27;In Conversation With&#x27; series is available to listen to below.<br>This week, Bruno Quinney speaks to Suzanne Caruso, President of Strategic Intelligence and Clinical &amp; Regulatory at Norstella. Norstella supports drug developers looking to take their treatments from pipeline to patients, finding solutions to complexities in the drug development timeline. One of these solutions is AI.<br>Suzanne discusses what it means for a company to be &#x27;AI-native&#x27;, how the combination of AI and Real World Data is transforming clinical development, and how AI is enabling companies to get treatments to patients faster.<br>You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.

How AI has revolutionised clinical development

The Drug Discovery World Podcast

Hello and welcome to the DDW Podcast, a podcast covering topics around drug discovery and development, pharma and biotech. I'm Bruno Quinney, thanks for joining me for today's episode. Today I'm in conversation with Suzanne Caruso, President of Strategic Intelligence and Clinical and Regulatory at Norstellar.

Norstellar supports drug developers who are looking to take their treatments from pipeline to patients, finding solutions to complexities in the drug development timeline. One of these solutions is AI. It's no understatement to say that AI is dominating all our conversations, and drug development is no different.

AI is largely being implemented to augment clinical trials and increase R&D efficiency. But why has it suddenly become so crucial? I spoke to Suzanne about what it means for a company to be AI native, how the combination of AI and real world data is transforming clinical development,

and how AI is enabling companies to get treatments to patients faster. This is the DDW Podcast. Well, Suzanne, thank you very much for joining us on the DDW Podcast. Could you start, please, by introducing yourself and talk to us about what your role at Norstellar entails?

Nice to see you, and I'm Suzanne Caruso. I'm the General Manager of Clinical, Regulatory and Strategic Intelligence at Norstellar. And what that really means day to day is I lead a business that really provides data and intelligence and insights to pharmaceutical companies, CROs, and financial services companies. So from your perspective, what does it actually mean for a company to be AI native? I mean, there's so many different definitions these days. But when a company really reaches being AI native,

How AI has revolutionised clinical development

Read the full transcript

The candid version is on a podcast,
not the earnings call.

How AI has revolutionised clinical development

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.